Fat cells can be damaged in a short amount of time when they are exposed to the fatty acid palmitate or the hormone TNF-alpha through a fatty diet, a new study shows. The researchers from Novo Nordisk Foundation Center for Basic Metabolic Research hope this new knowledge may be used to develop new preventive strategies for diabetes.
Philippe Leboulch, M.D., and colleagues report that a one-time treatment with the gene therapy known as LentiGlobin BB305 vector reduced or eliminated the need for blood transfusions in 22 patients with severe beta-thalassemia. The team's results are published in the April 19 issue of The New England Journal of Medicine.
Majority of patients with the most severe thalassemia are transfusion-free years after gene therapy that uses the patient's own stem cells.
Research sheds light on initial phase of infectious disease and potential for prevention of pneumococcal septicaemia.
Researchers engineered a donor cornea, introducing two genes intended to prevent new blood vessel formation following transplantation, and have shown this novel approach to be safe, well tolerated, and effective at reducing the risk of tissue rejection in a high-risk rabbit model.
An international group of researchers led by Cold Spring Harbor Laboratory Assistant Professor Gholson Lyon has identified a new genetic mutation associated with intellectual disability, developmental delay, autism spectrum disorder, abnormal facial features, and congenital cardiac anomalies.
Last year researchers from the University of Copenhagen discovered that a particular craving for sweet things may be determined by a genetic variation. Now the researchers, in collaboration with an English group, have discovered that people with this genetic disposition for a sweet tooth have less body fat.
Searching the entire genome, a Yale research team has identified a gene that when eliminated can spur regeneration of axons in nerve cells severed by spinal cord injury.
A newly discovered family of proteins -- present in humans and all complex animals -- are key players in controlling how stem cells specialise and in how embryos develop. These families of proteins may also represent key targets for drug developers looking to design new therapeutic options for some cancer patients.
Material left out of common processes for sequencing genetic material in cancer tumors may actually carry important information about why only some people respond to immunotherapy, possibly offering better insight than the type of material that is being sequenced, according to a study by Mount Sinai researchers published on April 3 in Cell Reports.